Literature DB >> 21871829

Phenylalanine hydroxylase deficiency: molecular epidemiology and predictable BH4-responsiveness in South Portugal PKU patients.

Isabel Rivera1, Dina Mendes, Ângela Afonso, Madalena Barroso, Ruben Ramos, Patrícia Janeiro, Anabela Oliveira, Ana Gaspar, Isabel Tavares de Almeida.   

Abstract

Hyperphenylalaninemia (HPA, OMIM #261600), which includes phenylketonuria (PKU), is caused by mutations in the gene encoding phenylalanine hydroxylase (PAH), being already described more than 600 different mutations. Genotype-phenotype correlation is a useful tool to predict the metabolic phenotype, to establish the better tailored diet and, more recently, to assess the potential responsiveness to BH(4) therapy, a current theme on PKU field. The aim of this study was the molecular analysis of the PAH gene, evaluation of genotype-phenotype relationships and prediction of BH(4)-responsiveness in the HPA population living in South Portugal. We performed the molecular characterization of 83 HPA patients using genomic DNA extracted from peripheral blood samples or Guthrie cards. PAH mutations were scanned by PCR amplification of exons and related intronic boundaries, followed by direct sequence analysis. Intragenic polymorphisms were determined by PCR-RFLP analysis. The results allowed the full characterization of 67 patients. The mutational spectrum encompasses 34 distinct mutations, being the most frequent IVS10nt-11G>A (14.6%), V388M (10.8%), R261Q (8.2%) and R270K (7.6%), which account for 46% of all mutant alleles. Moreover, 12 different haplotypes were identified and most mutations were associated with a single one. Notably, more than half of the 34 mutations belong to the group of more than 70 mutations already identified in BH(4)-responsive patients, according to BIOPKU database. Fifty one different genotypic combinations were found, most of them in single patients and involving a BH(4)-responsive mutation. In conclusion, a significant number (30-35%) of South Portugal PKU patients may potentially benefit from BH(4) therapy which, combined with a less strict diet, or eventually in special cases as monotherapy, may contribute to reduce nutritional deficiencies and minimize neurological and psychological dysfunctions.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21871829     DOI: 10.1016/j.ymgme.2011.07.026

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  9 in total

1.  Molecular Genetics and Genotype-Based Estimation of BH4-Responsiveness in Serbian PKU Patients: Spotlight on Phenotypic Implications of p.L48S.

Authors:  Maja Djordjevic; Kristel Klaassen; Adrijan Sarajlija; Natasa Tosic; Branka Zukic; Bozica Kecman; Milena Ugrin; Vesna Spasovski; Sonja Pavlovic; Maja Stojiljkovic
Journal:  JIMD Rep       Date:  2012-10-13

2.  Molecular epidemiology, genotype-phenotype correlation and BH4 responsiveness in Spanish patients with phenylketonuria.

Authors:  Luis Aldámiz-Echevarría; Marta Llarena; María A Bueno; Jaime Dalmau; Isidro Vitoria; Ana Fernández-Marmiesse; Fernando Andrade; Javier Blasco; Carlos Alcalde; David Gil; María C García; Domingo González-Lamuño; Mónica Ruiz; María A Ruiz; Luis Peña-Quintana; David González; Felix Sánchez-Valverde; Lourdes R Desviat; Belen Pérez; María L Couce
Journal:  J Hum Genet       Date:  2016-04-28       Impact factor: 3.172

3.  Phenylketonuria in Portugal: Genotype-phenotype correlations using molecular, biochemical, and haplotypic analyses.

Authors:  Filipa Ferreira; Luísa Azevedo; Raquel Neiva; Carmen Sousa; Helena Fonseca; Ana Marcão; Hugo Rocha; Célia Carmona; Sónia Ramos; Anabela Bandeira; Esmeralda Martins; Teresa Campos; Esmeralda Rodrigues; Paula Garcia; Luísa Diogo; Ana Cristina Ferreira; Silvia Sequeira; Francisco Silva; Luísa Rodrigues; Ana Gaspar; Patrícia Janeiro; António Amorim; Laura Vilarinho
Journal:  Mol Genet Genomic Med       Date:  2021-01-19       Impact factor: 2.183

4.  Quality of Life (QoL) assessment in a cohort of patients with phenylketonuria.

Authors:  Chiara Cazzorla; Luca Cegolon; Alessandro P Burlina; Andrea Celato; Pamela Massa; Laura Giordano; Giulia Polo; Aurora Daniele; Francesco Salvatore; Alberto B Burlina
Journal:  BMC Public Health       Date:  2014-12-04       Impact factor: 3.295

5.  Mutation analysis of Phenylalanine hydroxylase gene in Iranian patients with Phenylketonuria.

Authors:  Mahsa Rastegar Moghadam; Azadeh Shojaei; Vahid Babaei; Farzaneh Rohani; Farideh Ghazi
Journal:  Med J Islam Repub Iran       Date:  2018-03-11

6.  Genotype-phenotype correlations and BH4 estimated responsiveness in patients with phenylketonuria from Rio de Janeiro, Southeast Brazil.

Authors:  Eduardo Vieira Neto; Francisco Laranjeira; Dulce Quelhas; Isaura Ribeiro; Alexandre Seabra; Nicole Mineiro; Lilian M Carvalho; Lúcia Lacerda; Márcia G Ribeiro
Journal:  Mol Genet Genomic Med       Date:  2019-03-03       Impact factor: 2.183

7.  Mutations of the phenylalanine hydroxylase gene in Iranian patients with phenylketonuria.

Authors:  Alireza Biglari; Fatemeh Saffari; Zahra Rashvand; Safarali Alizadeh; Reza Najafipour; Mehdi Sahmani
Journal:  Springerplus       Date:  2015-09-23

8.  Molecular characterisation of phenylketonuria in a Chinese mainland population using next-generation sequencing.

Authors:  Nana Li; Haitao Jia; Zhen Liu; Jing Tao; Song Chen; Xiaohong Li; Ying Deng; Xi Jin; Jiaping Song; Liangtao Zhang; Yu Liang; Wei Wang; Jun Zhu
Journal:  Sci Rep       Date:  2015-10-27       Impact factor: 4.379

9.  Mutation analysis of the PAH gene in phenylketonuria patients from Rio de Janeiro, Southeast Brazil.

Authors:  Eduardo Vieira Neto; Francisco Laranjeira; Dulce Quelhas; Isaura Ribeiro; Alexandre Seabra; Nicole Mineiro; Lilian D M Carvalho; Lúcia Lacerda; Márcia G Ribeiro
Journal:  Mol Genet Genomic Med       Date:  2018-05-10       Impact factor: 2.183

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.